Hepatitis C


​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.  

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight
  • Genotype
  • Fibrosis Score

LABS

  • CBC
  • HDL
  • ALT / AST
  • HCV Viral Load
  • Platelets
  • Serum Creatinine
  • eGFR
  • HbA1C
  • SVR12 Outcome

PRIOR HISTORY

  • Prior Treatment Status
  • Prior Treatment Regimen
  • Duration of Therapy
  • Reason for Failure
  • Prior Transplant
  • Smoking Status
  • Illicit Drug Use

COMORBIDS

  • HIV Coinfection
  • Anxiety
  • Depression
  • Hypertension
  • Diabetes
  • Chronic Kidney Disease
  • Hyperlipidemia
  • Hemodialysis

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • Copay Amount
  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Gaps in Therapy

HCV Scientific Steering Committee


Trio’s unbiased insights have established a high level of integrity based on the Scientific Steering Committee expertise, diversity, and credibility to deliver transparent insight on the disease.

Nezam Afdhal, MD

  • Chairman – HCV Steering Committee
  • Professor of Medicine, Harvard Medical School
  • Beth Israel Deaconess Hospital (BIDMC) Boston, MA

Bruce Bacon, MD

  • James F. King, MD Endowed Chair in Gastroenterology at Saint Louis University (SLU), St. Louis, MO
  • Former President of the AASLD in 2004
  • Chair of the AASLD Foundation since 2013

Michael Curry, MD

  • Section Chief, Director of Liver Transplant, BIDMC, Boston MA
  • Associate Professor, Medicine, Harvard Medical School

Steven Flamm, MD

  • Professor of Medicine & Surgery, Division of Hepatology at Northwestern University, Chicago, IL
  • Chief of Transplantation Hepatology
  • Trustee of the AASLD Foundation

Naoky Tsai, MD

  • Private Practice – Honolulu, HI
  • Professor of Medicine – University of Hawaii

Zobair Younossi, MD, MPH

  • Chairman, Department of Medicine, Inova Fairfax Hospital, Fairfax, VA
  • Professor of Medicine, Virginia Commonwealth University
  • Chair of the Medical Advisory Committee of the National Capital Chapter of the ALF

COMMITTEE MEMBER ACCOMPLISHMENTS


Publication Journals

  • Annals of Internal Medicine
  • APS - American Physiological Society
  • Clinical Gastroenterology
  • Journal of Hepatology
  • World Journal of Gastroenterology
  • The New England Journal of Medicine
  • Liver International

Associations and Foundations

  • AASLD Foundation
  • American Board of Internal Medicine
  • ACG
  • ACP
  • AGA
  • American Liver Foundation
  • Hepatitis B Foundation
  • EASL
  • NIH

Advisory Board Affiliations

  • AbbVie
  • AEVI
  • Angion
  • Bristol-Myers Squibb
  • Gilead
  • Ligand
  • Merck
  • Salix
  • Spring Bank

Publications & Abstracts


2019

Access to HCV Cure Under Medicaid Programs in the United States

Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging (Oral Presentation)

Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network

Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the Trio Network

Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US

2018

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO Network

Preferences in clinical practice with glecaprevir/pibrentasvir (GLE-PIB), ledipasvir/sofosbuvir (LDF-SOF), and sofosbuvir/velpatasvir (SOF-VEL); data from the TRIO Network

Change in demographics of direct-acting antiviral (DAA) prescribed HCV patients from 2013 to 2018; data from 19,994 patients in the TRIO Network

Disparities in Accessing HCV care under Medicaid Programs Across the United States; Experience from the TRIO Network

Effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO Network

Untreated HCV in HIV/HCV co-infection; data from the TRIO Network

Behavioral and clinical factors and direct acting antiviral (DAA) effectiveness in HCV/HIV co-infection; clinical experience from the TRIO Network

Changing Demographics Among Prescribed Hepatitis C populations, 2013-2017

Use of Elbasvir-Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease (CKD): Retrospective Analyses from Clinical Practice

Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses From the TRIO Network

The impact of individual patient data in a network meta-analysis: An investigation into parameter estimation and model selection

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO Network

Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load <6mm IU/ml: Analyses of Real-World Data from the TRIO Network

Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in the Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

2017

Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network  

Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network

Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network                 

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)  

Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective data analyses from the Trio Network

Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network

HCV Treatment Failure in the era of direct-acting antivirals (DAAs): Analyses of real-world data from the TRIO Network   

Drivers of Therapy Choice in Genotype 1 HCV: Analyses of real-world data from the TRIO Network

Real-world patterns of therapy utilization and outcomes in 8,049 HCV patients: data from the TRIO Network

2016

No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients In the TRIO Network

Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network

Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network

Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network                

Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (G1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs)  

Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real-Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network

Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network

2015

Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network        

Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network

Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network 

Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network                

Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population

Evaluation of Access to Care in Patients Prescribed Sofosbuvir-containing Regimens; Data from the TRIO Network

Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network

Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network

Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network 

2014

Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network     

Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network